Sector Update: Healthcare Shares Flat Pre-Market; Merck Partners with GlaxoSmithKline

By
A A A
Share |

Healthcare stocks:

JNJ: +0.26%

PFE: flat

ABT: flat

MRK: flat

AMGN: flat

Healthcare shares are generally flat in pre-market trade.

Merck ( MRK ) has initiated a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's ( GSK ) orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

Merck and GlaxoSmithKline entered a collaboration to study MK-3475 with pazopanib and other agents in the GlaxoSmithKline portfolio in the future.

And, Depomed Inc. ( DEPO ) has acquired the U.S. rights to non-steroidal anti-inflammatory drug CAMBIA from Nautilus Neurosciences ( NLS ) for $48.7 million. In addition, DEPO may pay NLS up to an additional $5 million based on the achievement of certain annual net sales milestones.

DEPO expects the acquisition of CAMBIA to be immediately accretive and updated its year-end cash guidance to $272 million.

Shares are flat near the stock's 52-week high of $8.85. NLS is flat at $7.80.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: DEPO , GSK , MRK , NLS

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

100%
100%
100%
100%

Most Active by Volume

72,157,294
  • $61.36 ▼ 2.65%
56,535,455
  • $34.92 ▼ 3.78%
49,608,479
  • $4.42 ▼ 3.07%
49,328,445
  • $25.91 ▼ 3.18%
48,932,529
  • $16.37 ▲ 0.49%
38,182,422
  • $3.17 ▼ 1.55%
33,297,581
  • $73.86 ▲ 1.37%
32,790,375
  • $47.43 ▼ 1.02%
As of 4/23/2014, 04:07 PM